Omnicell (NASDAQ:OMCL) Issues FY24 Earnings Guidance

Omnicell (NASDAQ:OMCL) updated its FY24 earnings guidance on Thursday. The company provided EPS guidance of $0.90-1.40 for the period, compared to the consensus EPS estimate of $1.07. The company issued revenue guidance of $1.05-1.12 billion, compared to the consensus revenue estimate of $1.06 billion. Omnicell also updated its Q2 guidance to $0.10-0.20 EPS.

Omnicell Stock Up 2.9 %

Omnicell stock opened at $30.13 on Friday. Omnicell has a 1-year low of $25.69 and a 1-year high of $77.14. The company has a current ratio of 2.38, a quick ratio of 2.22 and a debt-to-equity ratio of 0.48. The firm has a 50-day moving average of $27.73 and a 200-day moving average of $31.72.

Omnicell (NASDAQ:OMCL) last announced its earnings results on Thursday, February 8th. The company reported $0.12 EPS for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.22. The company had revenue of $258.85 million during the quarter, compared to the consensus estimate of $256.00 million. Omnicell had a positive return on equity of 2.41% and a negative net margin of 1.91%. On average, equities analysts expect that Omnicell will post 0.09 earnings per share for the current fiscal year.

Analysts Set New Price Targets

OMCL has been the topic of several research analyst reports. Benchmark reiterated a buy rating and set a $38.00 price target on shares of Omnicell in a research report on Tuesday, April 30th. Wells Fargo & Company reduced their target price on Omnicell from $28.00 to $26.00 and set an equal weight rating on the stock in a report on Friday, February 9th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of Hold and a consensus price target of $42.20.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.